KYONGBO PHARMACEUTICAL CO., LTD.
Financials
Valuation Metrics
KYONGBO PHARMACEUTICAL CO., LTD.'s Market Cap is ₩1250B. At end of 2025 it was ₩1379B. Ranked #1087 of 2,436 in KR market (top 45%), #529 of 787 on KOSPI (top 67%), #128 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 55%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 125.03B KRW | KR#1,087/2,436 Sec#128/234 |
| Revenue | 269.64B KRW | KR#855/2,436 Sec#42/234 |
| Net Income | 347.4M KRW | KR#1,478/2,436 Sec#102/234 |
| Total Assets | 339.07B KRW | KR#943/2,436 Sec#60/234 |
| Net Assets | 144.29B KRW | KR#1,133/2,436 Sec#84/234 |
| Employees | 525 | KR#473/2,436 Sec#39/234 |
| Value | ||
| P/E | 359.91x | KR#1,491/2,436 Sec#104/234 |
| P/B | 0.87x | KR#1,365/2,436 Sec#84/234 |
| P/S | 0.46x | KR#875/2,436 Sec#32/234 |
| EV/EBITDA | 63.30x | KR#1,397/2,436 Sec#95/234 |
| FCF Yield | -27.26% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | 0.24% | KR#1,479/2,436 Sec#103/234 |
| ROA | 0.10% | KR#1,475/2,436 Sec#103/234 |
| Op. Margin | 1.52% | KR#1,417/2,436 Sec#104/234 |
| Revenue Growth | 9.14% | KR#957/2,436 Sec#84/234 |
| Earnings Growth | -89.59% | KR#1,350/2,436 Sec#88/234 |
| Financial Health | ||
| Debt Ratio | 134.99% | KR#945/2,436 Sec#110/234 |
| Total Debt | 140.34B KRW | KR#601/2,436 Sec#33/234 |
| FCF | -34.08B KRW | KR#2,023/2,436 Sec#197/234 |
| Cash | 5.20B KRW | KR#1,973/2,436 Sec#178/234 |
| Current Ratio | 0.94x | KR#1,886/2,436 Sec#189/234 |
| Net Debt/EBITDA | 32.88x | KR#1,490/2,436 Sec#106/234 |
| Dividend | ||
| Div. Yield | 0.98% | KR#1,142/2,436 Sec#68/234 |
| Div. Growth | 0.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | 2.35% | KR#665/2,436 Sec#48/234 |
| 1M Return | -0.95% | KR#993/2,436 Sec#93/234 |
| From 52W High | -43.76% | KR#925/2,436 Sec#69/234 |
| 1Y MDD | -42.16% | KR#600/2,436 Sec#46/234 |
| Trading | ||
| Volume | 29,187 shares | KR#1,666/2,436 Sec#163/234 |
| Foreign Own. | 1.48% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 15 KRW | KR#1,509/2,436 Sec#105/234 |
| BPS | 6,036 KRW | KR#1,300/2,436 Sec#92/234 |
Company Info
Established in 1987 as a specialized Active Pharmaceutical Ingredient (API) company, the company expanded into finished pharmaceutical products in 2002 and was renamed Kyung Bo Pharm. in 2007. It markets specialized pharmaceuticals, including cardiovascular drugs and inhalant anesthetics, along with various over-the-counter drugs, while exporting cephalosporin antibiotics like Ceftriaxone domestically and internationally from its API division. Kyung Bo Pharm. is diversifying into medical devices and animal health products, such as animal pharmaceuticals and nutritional supplements. Headquartered in Asan-si, Chungcheongnam-do, the company is developing ADC (Antibody-Drug Conjugate) anticancer drug technologies for entry into the global ADC CDMO market.